Icotinib: activity and clinical application in Chinese patients with lung cancer

Bibliography

• Chen W, Zheng R, Zhang S, et al. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res 2013;25:10-21
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention. United States Cancer Statistics (USCS), 2009 Top Ten Cancers. Available from: http://apps.nccd.cdc.gov/uscs/toptencancers.aspx
   Google Scholar
• D'Andrilli A, Venuta F, Rendina EA. The role of lymphadenectomy in lung cancer surgery. Thorac Surg Clin 2012;22:227-37
   PubMed Web of Science ®Google Scholar
• Cerfolio RJ, Bryant AS, Minnich DJ. Complete thoracic mediastinal lymphadenectomy leads to a higher rate of pathologically proven N2 disease in patients with non-small cell lung cancer. Ann Thorac Surg 2012;94:902-6
   PubMed Web of Science ®Google Scholar
• Kallianos A, Rapti A, Zarogoulidis P, et al. Therapeutic procedure in small cell lung cancer. J Thorac Dis 2013;5(Suppl 4):S420-4
   Web of Science ®Google Scholar
• Lwin Z, Riess JW, Gandara D. The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era. J Thorac Dis 2013;5(Suppl 5):S556-64
   PubMedGoogle Scholar
• Chan BA, Coward JI. Chemotherapy advances in small-cell lung cancer. J Thorac Dis 2013;5(Suppl 5):S565-78
   PubMedGoogle Scholar
• Kobayashi K, Hagiwara K. Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). Target Oncol 2013;8:27-33
   PubMed Web of Science ®Google Scholar
• Antonicelli A, Cafarotti S, Indini A, et al. EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation. Int J Med Sci 2013;10(3):320-30
   PubMed Web of Science ®Google Scholar
• Tan F, Shen X, Wang D, et al. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer 2012;76:177-82
   PubMed Web of Science ®Google Scholar
• Ren GJ, Zhao YY, Zhu YJ, et al. Tumor gene mutations and messenger RNA expression: correlation with clinical response toicotinib hydrochloride in non-small cell lung cancer. Chin Med J (Engl) 2011;124:19-25
   PubMed Web of Science ®Google Scholar
• Weltman JK. The 1986 nobel prize for physiology or medicine awarded for discovery of growth factors: Rita Levi-Montalcini, M.D., and Stanley Cohen, Ph.D. N Engl Reg Allergy Proc 1987;8:47-8
   PubMedGoogle Scholar
• Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990;265:7709-12
   PubMed Web of Science ®Google Scholar
• Cadena DL, Gill GN. Receptor tyrosine kinases. FASEB J 1992;6:2332-7
   PubMed Web of Science ®Google Scholar
• Johnson BE, Jänne PA. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res 2005;65:7525-9
   PubMed Web of Science ®Google Scholar
• Cooper WA, Lam DC, O'Toole SA, Minna JD. Molecular biology of lung cancer. J Thorac Dis 2013;5(Suppl 5):S479-90
   PubMedGoogle Scholar
• Thaker NG, Pollack IF. Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Rev Neurother 2009;9:1815-36
   PubMed Web of Science ®Google Scholar
• Cox AD, Der CJ. Ras history: the saga continues. Small GTPases 2010;1(1):2-27
   PubMedGoogle Scholar
• Matallanas D, Birtwistle M, Romano D, et al. Raf family kinases: old dogs have learned new tricks. Genes Cancer 2011;2(3):232-60
   PubMedGoogle Scholar
• Seshacharyulu P, Ponnusamy MP, Haridas D, et al. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:15-31
   PubMed Web of Science ®Google Scholar
• Freire E. Do enthalpy and entropy distinguish first in class from best in class? Drug Discov Today 2008;13:869-74
   PubMed Web of Science ®Google Scholar
• Garattini S. Are me-too drugs justified? J Nephrol 1997;10:283-94
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Faden LB. Competitiveness in follow-on drug R & D: a race or imitation? Nat Rev Drug Discov 2011;10:23-7
   PubMed Web of Science ®Google Scholar
• Giordanetto F, Boström J, Tyrchan C. Follow-on drugs: how far should chemists look? Drug Discov Today 2011;16:722-32
   PubMed Web of Science ®Google Scholar
• Camidge DR. Icotinib: kick-starting the chinese anticancer drug industry. Lancet Oncol 2013;14:913-14
   PubMed Web of Science ®Google Scholar
• Wang HP, Zhang L, Wang YX, et al. Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in chinese patients with non-small cell lung cancer. Chin Med J (Engl) 2011;124:1933
   PubMed Web of Science ®Google Scholar
• Dhomen NS, Mariadason J, Tebbutt N, Scott AM. Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit Rev Oncog 2012;17:31-50
   PubMedGoogle Scholar
• Paz-Ares L, Soulières D, Melezínek I, et al. Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med 2010;14:51-69
   PubMed Web of Science ®Google Scholar
• Qi WX, Shen Z, Lin F, et al. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev 2012;13:5177-82
   PubMed Web of Science ®Google Scholar
• Gao G, Ren S, Li A, et al. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials. Int J Cancer 2012;131:E822-9
   PubMed Web of Science ®Google Scholar
• Petrelli F, Borgonovo K, Cabiddu M, Barni S. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer 2012;13:107-14
   PubMed Web of Science ®Google Scholar
• Yang X, Zhang H, Qin N, et al. Clinical observation of icotinib hydrochloride in first-line therapy for pulmonary adenocarcinoma. Zhongguo Fei Ai Za Zhi 2013;16:364-8
   PubMedGoogle Scholar
• Abstracts of the 13th World Conference on Lung Cancer. July 31-August 4, 2009. San Francisco, California, USA. J Thorac Oncol 2009;4(9 Suppl 1):S5-968
   PubMedGoogle Scholar
• Guan Z, Chen X, Wang Y, Zhong D. Metabolite identification of a new antitumor agent icotinib in rats using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2008;22:2176-84
   PubMedGoogle Scholar
• Zhao Q, Shentu J, Xu N, et al. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer 2011;73:195-202
   PubMed Web of Science ®Google Scholar
• Ruan CJ, Liu DY, Jiang J, Hu P. Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers. Eur J Clin Pharmacol 2012;68:1677-80
   PubMed Web of Science ®Google Scholar
• Liu D, Jiang J, Zhang L, et al. Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry. Rapid Commun Mass Spectrom 2011;25:2131-40
   PubMedGoogle Scholar
• Song Z, Yu X, Cai J, et al. Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified. Zhongguo Fei Ai Za Zhi 2013;16:138-43
   PubMedGoogle Scholar
• Ma L, Han XH, Wang S, et al. Effects of icotinib hydrochloride on the proliferation and apoptosis of human lung cancer cell lines. Zhonghua Yi Xue Za Zhi 2012;92:2561-4
   PubMedGoogle Scholar
• Gao Z, Chen W, Zhang X, et al. Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling. Biomed Pharmacother 2013;67:351-6
   PubMed Web of Science ®Google Scholar
• Mu X, Zhang Y, Qu X, et al. Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer. Biomed Res Int 2013;2013:726375
   PubMed Web of Science ®Google Scholar
• Yang G, Yao Y, Zhou J, Zhao Q. Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer. Oncol Rep 2012;27:2066-672
   PubMed Web of Science ®Google Scholar
• Shi YK. Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting. Zhonghua Zhong Liu Za Zhi 2012;34:398-400
   PubMedGoogle Scholar
• Yang CL, Han XG, Yu CY. Effect of icotinib on cell cycle and expressions of CyclinD1, P27 in human tongue carcinoma cell line Tca8113. J Zhengzhou University (Medical Sciences) 2011;46:82-5
   Google Scholar
• Tan FL, Zhang L, Zhao Q, et al. Pharmacology and clinical evaluation of icotinib hydrochloride. Chinese J N Drugs 2009;18:1691-4
   Google Scholar
• Liu D, Jiang J, Hu P, et al. Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:3781-6
   PubMedGoogle Scholar
• Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 2013;14:953-61
   PubMed Web of Science ®Google Scholar
• Sun Y, Shi YK, Zhang L, et al. Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial. J Clin Oncol 2012;30(Suppl Pt 1):abstract 7559
   Google Scholar
• Lv C, Ma Y, Feng Q, et al. A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma. World J Surg Oncol 2013;11:96
   PubMed Web of Science ®Google Scholar
• Zheng Y, Fang W, Xu N. Hand-foot syndrome in a patient with metastatic lung adenocarcinoma induced by high-dose icotinib: a case report and review of the literature. Oncol Lett 2012;4:1341-3
   PubMed Web of Science ®Google Scholar
• Zhao Q, Wang YN, Wang B. Spared pre-irradiated area in pustular lesions induced by icotinib showing decreased expressions of CD1a+ langerhans cells and FGFR2. Jpn J Clin Oncol 2013;43:200-4
   PubMed Web of Science ®Google Scholar
• Takeda M, Okamoto I, Tsurutani J, et al. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Jpn J Clin Oncol 2012;42:528-33
   PubMed Web of Science ®Google Scholar
• Yamashita F, Sasa Y, Yoshida S, et al. Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data. PLoS one 2013;8:e70330
   PubMed Web of Science ®Google Scholar
• Gillam EM, Hayes MA. The evolution of cytochrome P450 enzymes as biocatalysts in drug discovery and development. Curr Top Med Chem 2013;13:2254-80
   PubMed Web of Science ®Google Scholar
• Isoherranen N, Lutz JD, Chung SP, et al. Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data. Chem Res Toxicol 2012;25:2285-300
   PubMed Web of Science ®Google Scholar
• Lu SS, Xu X, Guo HQ, et al. Detection of EGFR and K-ras mutations in non-small cell lung cancer using cytological specimens. Zhonghua Zhong Liu Za Zhi 2013;35:585-9
   PubMedGoogle Scholar
• Zhou W, Christiani DC. East meets west: ethnic differences in epidemiology and clinical behaviors of lung cancer between east asians and caucasians. Chin J Cancer 2011;30:287-92
   PubMedGoogle Scholar
• Ma L, Liu L, Zhang T, Shan L. Detection and evaluation of EGFR mutation status in serum of patients with advanced non-small cell lung cancer treated with EGFR-TKIs. Zhongguo Fei Ai Za Zhi 2013;16:303-7
   PubMedGoogle Scholar
• Nong J, Qin N, Wang J, et al. Clinical effects for patients with recurrent advanced non-small cell lung cancer treated with icotinib hydrochloride. Zhongguo Fei Ai Za Zhi 2013;16:240-5
   PubMedGoogle Scholar
• Shi YK. Icotinib hydrochloride (conmana): experts consensus based on clinical application in China. Chinese J N Drugs 2012;21:578
   Google Scholar
• Zheng Y, Fang W, Liu X, Xu N. New EGFR-TKI: a case report of recurrent lung adenocarcinoma successfully treated with icotinib. Tumori 2012;98:e102-4
   Google Scholar
• Gu A, Shi C, Xiong L, et al. Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer. Chin J Cancer Res 2013;25:90-4
   PubMed Web of Science ®Google Scholar
• Li X, Yang XJ, Sun YF, et al. Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2012;34:627-31
   PubMedGoogle Scholar
• Li J, Guo Z. Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase. Zhongguo Fei Ai Za Zhi 2012;15:305-8
   PubMedGoogle Scholar
• Sun X, Zheng Y. Retreatment with icotinib in a patient with metastatic lung adenocarcinoma. Tumori 2013;99:124e-6e
   Google Scholar
• Initiation of phase IV clinical trial of Conmana, small molecular targeted antitumor drug independently developed in China. Chinese J N Drugs 2011;22:1
   Google Scholar
• Tang C, Li X, Guo W, et al. How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI? Zhongguo Fei Ai Za Zhi 2013;16:345-52
   PubMedGoogle Scholar
• Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter? J Clin Oncol 2013;31:1112-21
   PubMed Web of Science ®Google Scholar
• Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008;9:962-72
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 2013;79C:34-74
   Google Scholar
• Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004;319:1-11
   PubMed Web of Science ®Google Scholar
• Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. ErbB/HER receptor family in breast cancer--the more we search the more we learn. Ann Oncol 2008;19:1020-1
   PubMedGoogle Scholar
• Goldenberg MM. Pharmaceutical approval update. PT 2013;38:518-24
   PubMedGoogle Scholar
• Morgillo F, Sasso FC, Della Corte CM, et al. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin Cancer Res 2013;19:3508-19
   PubMed Web of Science ®Google Scholar
• Dong S, Zhang XC, Cheng H, et al. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Chemother Pharmacol 2012;70:707-16
   PubMed Web of Science ®Google Scholar
• Yoshimura N, Okishio K, Mitsuoka S, et al. Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed. J Thorac Oncol 2013;8(1):96-101
   PubMed Web of Science ®Google Scholar
• Huang Z, Brdlik C, Jin P, Shepard HM. A pan-HER approach for cancer therapy: background, current status and future development. Expert Opin Biol Ther 2009;9(1):97-110
   PubMed Web of Science ®Google Scholar
• Cha MY, Lee KO, Kim M, et al. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer 2012;130:2445-54
   PubMed Web of Science ®Google Scholar
• Panosa C, Tebar F, Ferrer-Batallé M, et al. Development of an epidermal growth factor derivative with EGFR blocking activity. PLoS One 2013;8:e69325
   Web of Science ®Google Scholar
• Pęksa A, Kita A, Kułakowska K, et al. The quality of protein of coloured fleshed potatoes. Food Chem 2013;141:2960-6
   PubMed Web of Science ®Google Scholar
• Kowalczewski P, Celka K, Białas W, Lewandowicz G. Antioxidant activity of potato juice. Acta Sci Pol Technol Aliment 2012;11:175-81
   PubMedGoogle Scholar
• García-Estévez I, Escribano-Bailón MT, Rivas-Gonzalo JC, Alcalde-Eon C. Development of a fractionation method for the detection and identification of oak ellagitannins in red wines. Anal Chim Acta 2010;660:171-6
   PubMed Web of Science ®Google Scholar
• Fridrich D, Glabasnia A, Fritz J, et al. Oak ellagitannins suppress the phosphorylation of the epidermal growth factor receptor in human colon carcinoma cells. J Agric Food Chem 2008;56:3010-15
   PubMed Web of Science ®Google Scholar